source
- Novo Nordisk sues Eli Lilly over alleged misleading obesity drug adsNovo Nordisk filed a lawsuit in a New Jersey federal court accusing Eli Lilly of deceptive advertising for its GLP-1 obesity medicines. The action follows a cease-and-desist request that asked Lil…
- Agios halts development of sickle cell drug tebapivat after mid-stage trial failureAgios announced it will stop developing tebapivat for sickle cell disease after a mid-stage trial did not meet expectations. The drug, a next-generation pyruvate kinase activator related to the ap…